```
* * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * *
SESSION RESUMED IN FILE 'HOME' AT 16:00:58 ON 05 OCT 2006
FILE 'HOME' ENTERED AT 16:00:58 ON 05 OCT 2006
ENTER A FILE NAME OR (IGNORE):medline caplus embase biosis uspatful
COST IN U.S. DOLLARS                    SINCE FILE     TOTAL
                                        ENTRY   SESSION
FULL ESTIMATED COST                       1.47      1.47

FILE 'MEDLINE' ENTERED AT 16:01:37 ON 05 OCT 2006

FILE 'CAPLUS' ENTERED AT 16:01:37 ON 05 OCT 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 16:01:37 ON 05 OCT 2006
Copyright (c) 2006 Elsevier B.V. All rights reserved.

FILE 'USPATFULL' ENTERED AT 16:01:37 ON 05 OCT 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 16:01:37 ON 05 OCT 2006
Copyright (c) 2006 The Thomson Corporation

COST IN U.S. DOLLARS                    SINCE FILE     TOTAL
                                        ENTRY   SESSION
FULL ESTIMATED COST                       4.58      6.05

=> s  interferon-beta or IFN (w) beta or IFn-beta
L1      35200 INTERFERON-BETA OR IFN (W) BETA OR IFN-BETA

=> s l1 (w) treat?
L2       1366 L1 (W) TREAT?

=> duplicate remove l2
DUPLICATE PREFERENCE IS 'MEDLINE, CAPLUS, EMBASE, USPATFULL,
BIOSIS'
KEEP DUPLICATES FROM MORE THAN ONE FILE?  Y/(N):n
PROCESSING COMPLETED FOR L2
L3        639 DUPLICATE REMOVE L2 (727 DUPLICATES REMOVED)

=> s l3 (W) (infection? or tumor? or cancer or autoimmune or inflammatory)
L4          3 L3 (W) (INFECTION? OR TUMOR? OR CANCER OR AUTOIMMUNE
OR INFLAMM
            ATORY)
```

=> d l4 1- ibib, abs
YOU HAVE REQUESTED DATA FROM 3 ANSWERS - CONTINUE? Y/(N):y

L4 ANSWER 1 OF 3 MEDLINE on STN
ACCESSION NUMBER: 2006269606 IN-PROCESS <<LOGINID::20061005>>
DOCUMENT NUMBER: PubMed ID: 16698995
TITLE: Differentially regulated interferon response determines the outcome of Newcastle disease virus infection in normal and tumor cell lines.
AUTHOR: Krishnamurthy Sateesh; Takimoto Toru; Scroggs Ruth Ann; Portner Allen
CORPORATE SOURCE: Department of Infectious Diseases, Mail Stop 330, St. Jude Children's Research Hospital, 332 N. Lauderdale, Memphis, TN 38105-2794, USA.
CONTRACT NUMBER: AI 055940 (NIAID)
AI 38956 (NIAID)
SOURCE: Journal of virology, (2006 Jun) Vol. 80, No. 11, pp. 5145-55.
Journal code: 0113724. ISSN: 0022-538X.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: NONMEDLINE; IN-PROCESS; NONINDEXED; Priority Journals
ENTRY DATE: Entered STN: 16 May 2006
Last Updated on STN: 2 Jun 2006
AB Newcastle disease virus (NDV) is a negative-strand RNA virus with oncolytic activity against human tumors. Its effectiveness against tumors and safety in normal tissue have been demonstrated in several clinical studies. Here we show that the spread of NDV infection is drastically different in normal cell lines than in tumor cell lines and that the two cell types respond differently to beta interferon (IFN-beta) treatment. NDV rapidly replicated and killed HT-1080 human fibrosarcoma cells but spread poorly in CCD-1122Sk human skin fibroblast cells. Pretreatment with endogenous or exogenous IFN-beta completely inhibited NDV replication in normal cells but had little or no effect in tumor cells. Thus, the outcome of NDV infection appeared to depend on the response of uninfected cells to IFN-beta. To investigate their differences in IFN responsiveness, we analyzed and compared the expression and activation of components of the IFN signal transduction pathway in these two types of cells. The levels of phosphorylated STAT1 and STAT2 and that of the ISGF3 complex were markedly reduced in IFN-beta-treated tumor cells. Moreover, cDNA microarray analysis revealed significantly fewer IFN-regulated genes in the HT-1080 cells than in the CDD-1122Sk cells. This finding suggests that tumor cells demonstrate a less-than-optimum antiviral response because of a lesion in

their IFN signal transduction pathway. The rapid spread of NDV in HT-1080 cells appears to be caused by their deficient expression of anti-NDV proteins upon exposure to IFN-beta.

L4 ANSWER 2 OF 3 USPATFULL on STN
ACCESSION NUMBER: 2006:104371 USPATFULL <<LOGINID::20061005>>
TITLE: Treatment screening methods
INVENTOR(S): Dowding, Charles, San Diego, CA, UNITED STATES
Frincke, James M., San Diego, CA, UNITED STATES
Garsd, Armando, San Diego, CA, UNITED STATES
Reading, Christopher L., San Diego, CA, UNITED STATES
Stickney, Dwight R., Granite Bay, CA, UNITED STATES
Ahlem, Clarence N., San Diego, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006088473	A1	20060427
APPLICATION INFO.:	US 2005-242547	A1	20051003 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2004-615307P	20041001 (60)
	US 2004-628252P	20041115 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HOLLIS-EDEN PHARMACEUTICALS, INC., 4435 EASTGATE MALL,
SUITE 400, SAN DIEGO, CA, 92121, US
NUMBER OF CLAIMS: 27
EXEMPLARY CLAIM: 1
LINE COUNT: 13655
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention includes a method to identify a method to enhance survival of a subject such as a non-human primate that has been exposed to a biological insult such as an ionizing radiation dose of about LD.sub.30/30 or about LD.sub.50/30 by treating the exposed subject with a test compound an optionally comparing the results to that obtained using control subjects that had been treated with 3b,17b-dihydroxyandrost-5-ene or other disclosed compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 3 OF 3 USPATFULL on STN
ACCESSION NUMBER: 2006:86100 USPATFULL <<LOGINID::20061005>>
TITLE: Treatment screening methods
INVENTOR(S): Frincke, James M., San Diego, CA, UNITED STATES

Dowding, Charles, San Diego, CA, UNITED STATES
Garsd, Armando, San Diego, CA, UNITED STATES
Reading, Christopher L., San Diego, CA, UNITED STATES
Stickney, Dwight R., Granite Bay, CA, UNITED STATES
Ahlem, Clarence N., San Diego, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006073099	A1	20060406
APPLICATION INFO.:	US 2005-241678	A1	20050930 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2004-615307P	20041001 (60)
	US 2004-628252P	20041115 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HOLLIS-EDEN PHARMACEUTICALS, INC., 4435 EASTGATE MALL,
SUITE 400, SAN DIEGO, CA, 92121, US
NUMBER OF CLAIMS: 21
EXEMPLARY CLAIM: 1
LINE COUNT: 14754
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention includes a method to identify a method to enhance survival of a subject that has been exposed to a biological insult such as an ionizing radiation dose of LD.sub.50/30 by treating the exposed subject with a test compound an optically comparing the results to that obtained using control subjects that had been treated with 3b,17b-dihydroxyandrost-5-ene or other disclosed compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> s 3 L3 (A) (INFECTION? OR TUMOR? OR CANCER OR AUTOIMMUNE OR INFLAMMATORY)
MISSING OPERATOR 3 L3
The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.

=> s L3 (A) (INFECTION? OR TUMOR? OR CANCER OR AUTOIMMUNE OR INFLAMMATORY)
L5 3 L3 (A) (INFECTION? OR TUMOR? OR CANCER OR AUTOIMMUNE OR INFLAMM
ATORY)

=> s L3 and (INFECTION? OR TUMOR? OR CANCER OR AUTOIMMUNE OR INFLAMMATORY)
L6 349 L3 AND (INFECTION? OR TUMOR? OR CANCER OR AUTOIMMUNE OR INFLAMM
ATORY)